
Zura Bio keeps 2028 cash runway ahead of year‑end tibulizumab data
US$187.7M in cash supports planned operations as two fully enrolled autoimmune trials approach readouts and a third study awaits its start.

Indiana-made cells and modules are due by the end of 2026, ahead of the buyer's planned construction starts in 2027.

US$187.7M in cash supports planned operations as two fully enrolled autoimmune trials approach readouts and a third study awaits its start.

Australian government lenders back part of a proposed A$200 million debt package, with commercial financing and final approvals still required.
CoreWeave's Oct. 27 announcement gives no local customer revenue, project costs or billing dates for the Copenhagen deployment.
The South Texas satellite plant and first wellfield are built, with uranium extraction expected shortly after receipt of the final permit.

A planned 72-participant study will test four subcutaneous doses, with safety and tolerability assessed over 48 weeks.

Profit fell from US$505 million a year earlier, while cash, stablecoins and Treasuries reached US$4.9 billion.

Adjusted operating income turned positive, but an insurance benefit lifted cash generation and the IFRS net loss reached C$50.8 million.

The 523-patient study met its progression-free survival endpoint, but Pfizer withheld the comparative effect size and a filing date.
Eight holes outlined mineralization across 200 metres of strike at Hatchet Lake South, with follow-up targets to the north and south.
The denial leaves the state water-quality certification vacated, while Williams' project page still targets service in late 2027.
The venture's first customer has paid an undisclosed deposit for Dallas GPU capacity expected to deploy in late December or early January.
Eco DC Solutions says capacity would exceed 2.1 GW; its Oct. 26 release omits equipment prices, binding purchase terms and delivery dates.
Common-stock cash would arrive at forward settlement, while a proposed Class C sale program has no agreement or settled terms.
Separate mine, plant, water and infrastructure approvals remain outstanding ahead of a targeted production decision in early 2027.
Ocean Partners would own about 6.5 per cent before warrant exercise, with proceeds supporting Steller exploration and a study in the first half of 2027.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
A 21.75-metre drill interval grades 2.73 grams per tonne, while assays from 44 holes remain pending at the Yukon project.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
A pooled analysis of 139 treated adults showed sustained filtration gains, but long-term follow-up had no continuing placebo comparison.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The proposed hardware and software combination is expected to close in the first half of 2027, subject to regulatory approvals.
About 60,000 employees are reportedly eligible, with decisions due in early December and departures set for Dec. 31.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Google will fund flexible household and business resources in PJM, but the companies disclose no price or delivery schedule.

Fortum's jointly owned disposal company must complete commissioning and pass a STUK inspection before operations can begin.

The reactor developer targets Oct. 30 for the remaining six chapters and retains its company-set 2027 deployment goal.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Directors retain discretion over the ratio for common and exchangeable shares, with no effective date set in the voting disclosure.

The capsules are intended for three programs, including a Canadian Phase 3 PTSD trial of up to 100 people expected to begin in 2027.

The province estimates illegal retailers take 30 per cent of cannabis sales and proposes inspection, seizure and penalty powers for the AGCO.

The bid offers US$1 in cash plus 0.4013 Curaleaf shares for each Aurora share, with a Dec. 4 tender deadline.